 Vanessa Fabrizio
Concepts (71)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 12 | 2025 | 343 | 1.860 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2023 | 297 | 1.660 |
Why?
| | Receptors, Antigen, T-Cell | 12 | 2025 | 673 | 1.630 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2026 | 699 | 1.180 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 61 | 0.850 |
Why?
| | Graft vs Host Disease | 3 | 2026 | 279 | 0.830 |
Why?
| | Cytomegalovirus | 1 | 2021 | 168 | 0.610 |
Why?
| | Cytomegalovirus Infections | 1 | 2021 | 206 | 0.570 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2025 | 89 | 0.560 |
Why?
| | Bone Marrow Transplantation | 1 | 2018 | 298 | 0.500 |
Why?
| | Bone Marrow | 1 | 2018 | 307 | 0.490 |
Why?
| | Graft Survival | 1 | 2018 | 519 | 0.460 |
Why?
| | Antigens, CD19 | 4 | 2025 | 128 | 0.460 |
Why?
| | Child | 21 | 2026 | 22740 | 0.400 |
Why?
| | Recurrence | 5 | 2025 | 1139 | 0.390 |
Why?
| | Retrospective Studies | 15 | 2025 | 17330 | 0.360 |
Why?
| | T-Lymphocytes | 5 | 2024 | 1998 | 0.350 |
Why?
| | Young Adult | 13 | 2026 | 14254 | 0.300 |
Why?
| | Infant | 8 | 2025 | 10091 | 0.270 |
Why?
| | Child, Preschool | 10 | 2026 | 11868 | 0.260 |
Why?
| | Neoplasms | 2 | 2021 | 2913 | 0.240 |
Why?
| | Adolescent | 14 | 2026 | 22577 | 0.240 |
Why?
| | Neuronal Ceroid-Lipofuscinoses | 1 | 2025 | 5 | 0.220 |
Why?
| | Neutropenia | 1 | 2025 | 154 | 0.210 |
Why?
| | Stem Cell Transplantation | 1 | 2025 | 189 | 0.210 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2026 | 218 | 0.210 |
Why?
| | Neuroblastoma | 1 | 2025 | 174 | 0.210 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2025 | 103 | 0.200 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 29 | 0.190 |
Why?
| | Humans | 23 | 2026 | 145783 | 0.180 |
Why?
| | Vidarabine | 1 | 2022 | 32 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 76 | 0.170 |
Why?
| | Immunotherapy | 1 | 2025 | 668 | 0.160 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2021 | 177 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 198 | 0.150 |
Why?
| | Antigens, CD34 | 1 | 2018 | 90 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 688 | 0.140 |
Why?
| | Cognition Disorders | 1 | 2022 | 544 | 0.130 |
Why?
| | Cognition | 1 | 2026 | 1271 | 0.130 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 419 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2025 | 11794 | 0.120 |
Why?
| | Genomics | 1 | 2021 | 830 | 0.120 |
Why?
| | Adult | 9 | 2026 | 40881 | 0.110 |
Why?
| | Blood Platelets | 1 | 2018 | 379 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2018 | 435 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 1146 | 0.100 |
Why?
| | Quality of Life | 1 | 2026 | 3211 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1150 | 0.100 |
Why?
| | Neutrophils | 1 | 2018 | 1127 | 0.090 |
Why?
| | Chronic Disease | 3 | 2023 | 1812 | 0.090 |
Why?
| | Male | 10 | 2026 | 73011 | 0.090 |
Why?
| | Female | 10 | 2026 | 79045 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3418 | 0.080 |
Why?
| | Prospective Studies | 1 | 2022 | 8078 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2025 | 50 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2025 | 301 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2025 | 322 | 0.050 |
Why?
| | Cell Lineage | 1 | 2025 | 378 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2023 | 172 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 428 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2025 | 1115 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 735 | 0.040 |
Why?
| | Cost of Illness | 1 | 2021 | 324 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2022 | 1137 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2026 | 5428 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3752 | 0.030 |
Why?
| | United States | 2 | 2023 | 16126 | 0.030 |
Why?
| | Risk Factors | 1 | 2025 | 10919 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 6465 | 0.020 |
Why?
| | Aged | 1 | 2025 | 26217 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 36309 | 0.010 |
Why?
|
|
Fabrizio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|